コーパス検索結果 (right1)
通し番号をクリックするとPubMedの該当ページを表示します
3 The primary endpoint was assessed in all patients who received at least one dose of combination th
4 and tolerability were assessed in the safety analysis set (all patients who received at least one dose of gilteritinib).
5 mary outcomes were pharmacokinetics and safety, analysed in all patients who received at least one dose of ivacaftor.
10 tention-to-treat population, whereas safety was analysed in all patients who received at least one dose of study drug and
12 and HbA1c measured in the full analysis set, which included all patients who received at least one dose of study drug and
13 dose of study drug were included in the safety analysis and all patients who received at least one dose of study drug and
14 Responses were assessed in the full analysis set (all patients who received at least one dose of study drug and
18 mpty from the stomach), measured at 5 weeks and 16 weeks in all patients who received at least one dose of study drug, wi
21 ed by intention to treat and the safety population included all patients who received at least one dose of study drug.
22 sis was by intention to treat, and safety analysis included all patients who received at least one dose of study drug.
25 cale-Revised) and overall survival, analysed at 48 weeks in all patients who received at least one dose of study drug.
27 analyses were done based on the safety set, which included all patients who received at least one dose of study drug.
32 ith SVR12; the primary endpoint and safety were assessed in all patients who received at least one dose of study drugs.
34 he intention-to-treat population and safety was assessed in all patients who received at least one dose of study treatmen
35 n the intention-to-treat population; safety was analysed in all patients who received at least one dose of study treatmen
36 The key exploratory PRO endpoints (analysed for all patients who received at least one dose of study treatmen
37 up HSCT) and after study treatment and subsequent HSCT, for all patients who received at least one dose of study treatmen
40 afety was assessed in the as-treated population, defined as all patients who received at least one dose of the assigned s
42 andomly assigned to treatment; safety analyses were done in all patients who received at least one dose of the study drug
43 The safety and efficacy analyses were done on all patients who received at least one dose of the study drug
45 icity were analysed in the safety population, consisting of all patients who received at least one dose of their randomis
47 nalysed randomly assigned patients for overall survival and all patients who received at least one dose of treatment for
50 r protocol for all patients who commenced drug and included all patients who received at least one dose of venetoclax.
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。